← Back to all trials
Recruiting
NCT07800754
A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Sex: All
Ages: 18 Years – 130 Years
Healthy volunteers: No
Enrollment: 300
Sponsor: AstraZeneca
Location: Research Site Alexandroupoli
Summary
This is a retrospective-prospective observational, multicenter, single-country study aiming to describe the epidemiological characteristics and management strategies in patients with stage II-IVB gastric/GEJ adenocarcinoma in routine clinical practice in Greece.
Eligibility Criteria
Inclusion Criteria:
* Patients aged ≥18 years upon gastric/GEJ adenocarcinoma diagnosis.
* Written signed and dated informed consent by the patient (or their legally acceptable representative, as applicable). For deceased patients on the date of study entry a waiver of consent must be approved by the Hospital EC/IRB.
* Patients diagnosed with histologically confirmed, stage II to IVB adenocarcinoma of gastric/GEJ, between June 1st, 2025 and the end of the recruitment period (Q3 2027).
Exclusion Criteria:
* Patients who participate or participated during the data collection period (prospective and retrospective) in any clinical investigation/clinical trial that includes interventions that fall outside the everyday clinical practice.
* Patients who have participated in the design and/or the conduct of the study.
* Patients with another primary malignancy within the last 5 years, for which systemic anticancer treatment is required after the diagnosis of gastric/GEJ cancer.
Source: ClinicalTrials.gov (NCT07800754). StuddyBuddy aggregates publicly available trial information.